Clinical trials: Metabolic Parameters
Glucose Parameters, Triglycerides
Investigating the Effects of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight
This study is investigating the effects of 8 weeks of supplementation with Glucodia™, on glucose parameters, triglycerides and body weight as compared to a placebo.
- Conditions
- Glucose Parameters, Triglycerides, Body Weight
- Trial name
- 14GGHF (NCT02322294)
- Testing
- Glucodia™
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Diabetes Mellitus Type 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00800176
- Testing
- RO4998452
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04862923)
- Testing
- Oral semaglutide
- Where
- United Kingdom
- Volunteers
- 336 people
- Sponsor
- Novo Nordisk A/S
Dyslipidemia
Effect of Compound (Cardiol Forte) on Lipid And Glycemic Parameters in Low Cardiovascular Risk Individuals
This study will evaluate the effects of a combination dietary supplement, Cardiol Forte, on lipid and glycemic parameters in adults at low cardiovascular risk with suboptimal cholesterol levels.
- Trial name
- CLARISKI (NCT07515573)
- Testing
- Cardiol Forte
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- U.G.A. Nutraceuticals
Gaucher's Disease
A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth
A study to assess the absorption of eliglustat through the mouth in healthy subjects and the safety of any systemic exposure resulting from oral surface absorption of eliglustat in healthy subjects.
- Trial name
- Acronym (NCT06193304)
- Testing
- Eliglustat
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes
Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar
The prevalence of type 2 diabetes (T2DM) is increasing sharply around the world and obesity and sedentary lifestyles are driving the epidemic. Obesity is often, but not always present in patients with T2DM.
- Trial name
- NCT04081064
- Testing
- 10-week exercise programme based on aerobic interval and resistance training
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Diabetes
Performance Evaluation of Lucie™ for Hydration of Dialysis Patients
The main objective of the observatory study is to evaluate the performance of the Lucie™ medical device for measuring water balance before and after dialysis (water overload, dry weight) in patients with chronic renal failure.
- Trial name
- PERF-LUCIE (NCT06640270)
- Testing
- Diabetes Treatment
- Volunteers
- 150 people
- Sponsor
- Home Habilis
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT05443568)
- Testing
- Oral semaglutide
- Where
- Israel
- Volunteers
- 155 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia
The purpose of this study is to investigate the glycaemic control and other clinical parameters in adult patients previously treated with basal insulin (with or without OADs) and switched to IDegLira in real-world clinical…
- Trial name
- SPIRIT (NCT05324462)
- Testing
- IDegLira
- Where
- 6 sites in Colombia
- Volunteers
- 175 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor.
- Trial name
- NCT06807190
- Testing
- Insulin Icodec
- Where
- 116 sites in Japan
- Volunteers
- 630 people
- Sponsor
- Novo Nordisk A/S
Osteoporosis
A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo
This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved…
- Trial name
- NCT00365924
- Testing
- Forteo
- Where
- 3 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- Pfizer
Healthy
Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
- Trial name
- NCT01819922
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study To Evaluate PF-05175157 In Healthy Volunteers
The primary purpose of this study is to evaluate the pharmacodynamics of single oral doses of PF-05175157 in healthy volunteers
- Trial name
- NCT01433380
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus Type 2
A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.
This 5 arm study will assess the efficacy, pharmacokinetics, safety and tolerability of a DPP-IV inhibitor compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00502710
- Testing
- RO4876904
- Where
- 48 sites in United States, Australia and 7 more
- Volunteers
- 289 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
TC-6987 is a selective nicotinic α-7 receptor ligand (open channel stabilizer) that has demonstrated potent anti-inflammatory/antioxidant properties in animal models.
- Trial name
- NCT01293669
- Testing
- TC-6987
- Where
- 18 sites in United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Hypertension, Metabolic Disorder
A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)
To determine if a one year treatment Losartan with or without HCTZ at different dosages have an effect on metabolic parameters in patients with hypertension and the metabolic syndrome.
- Trial name
- NCT00546052
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 1,738 people
- Sponsor
- Organon and Co
Diabetes Mellitus, Type 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.
A single blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic parameters of repeat doses of GSK2330672 in healthy volunteers, given alone and with…
- Trial name
- NCT01607385
- Testing
- GSK2330672, GSK1614235
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Other Endocrine/Nutritional/Metabolic Disorder
Nutritional Supplement Impact on Metabolic Parameters
This open label study seeks to study the effects of a nutritional supplement on inflammatory markers, metabolic parameters, and safety in subjects compared to baseline after taking supplement for 2 and 4 months.
- Trial name
- NCT02349555
- Testing
- Nutritional Supplement Blend
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Diabetes, Peripheral Vascular Disease
Open-label Pilot Study to Assess the Use of Magic Foot™ in the Improvment of Parameters in Subject With Foot Symptoms
This is a single-arm, single-center, open-label, pilot study . 30 subjects with foot symptoms attributable to diabetes or peripheral vascular disease will be screened .
- Trial name
- MF (NCT01784471)
- Testing
- Magic Foot™
- Where
- Israel
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Yaffa Golan, Ltd.
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower participants blood sugar levels.
- Trial name
- PIONEER REAL (NCT04559815)
- Testing
- Oral Semaglutide
- Where
- 2 sites in Canada
- Volunteers
- 194 people
- Sponsor
- Novo Nordisk A/S